



Take high-quality mass spectrometry to a new level: accelerating drug discovery




On average, it takes 10-15 years and 1-2 billion dollars to approve a new pharmaceutical for clinical use.¹ Since approximately 90% of new drug candidates fail in clinical development, the ability to make early, informed and accurate decisions on the safety and efficacy of new hits and leads is key to increasing the chances of success.²

This infographic explores the benefits of Acoustic Ejection Mass Spectrometry (AEMS)-based workflows for efficient small and large molecule screening.

Why is high-throughput screening needed?


Drug discovery demands high-quality data, system reliability and speed at the lowest possible cost. By driving key decisions earlier in the process, these attributes increase the likelihood of developing successful clinical candidates.




Addressing the challenges of traditional methods

Key decisions about drug candidates depend on the quality of the analytical data. Fluorescence-based assays have been the gold standard for hit identification but can be prone to false positives. This has driven the need for an alternative, label-free technique that combines speed and sensitivity, is simple to implement and has enhanced data reliability.

The Echo® MS+ systems produce results with the precision and accuracy required for drug discovery.



Optimizing high-throughput mass spectrometry screening



Streamlining drug discovery with innovative mass spectrometry solutions

Available in two configurations to best suit your requirements

<p>Echo® MS+ system with ZenoTOF 7600 system</p> <p>Best suited for:</p> <p>High-resolution targeted screening:</p> <ul style="list-style-type: none"> HTS – Small molecule HTS – Intact proteins Medicinal chemistry Compound quality assessment <p>Additional benefits:</p> <ul style="list-style-type: none"> Reduce background interference with increased specificity and selectivity Ease of method development [MS method] 	<p>Echo® MS+ system with SCIEX Triple Quad 6500+ mass spectrometer</p> <p>Best suited for:</p> <p>Absolute sensitivity for quantitative work:</p> <ul style="list-style-type: none"> HTS biochemical assays <p>Additional benefits:</p> <ul style="list-style-type: none"> Simplicity of general system operation Higher level of quantitative consistency
--	--

References

- Sun D, Gao W, Hu H, Zhou S. Why 90% of clinical drug development fails and how to improve it? *Acta Pharmaceutica Sinica B*. 2022;12(7):3049-3062. doi:10.1016/j.apsb.2022.02.002
- Lowé D. The latest on drug failure and approval rates. <https://www.science.org/content/blog-post/latest-drug-failure-and-approval-rates>. Published May 9 2019. Accessed October 28, 2022.

The SCIEX clinical diagnostic portfolio is For In Vitro Diagnostic Use. Rx Only. Product(s) not available in all countries. For information on availability, please contact your local sales representative or refer to www.sciex.com/diagnostics. All other products are For Research Use Only. Not for use in Diagnostic Procedures. Trademarks and/or registered trademarks mentioned herein, including associated logos, are the property of AB Sciex Pte. Ltd. or their respective owners in the United States and/or certain other countries [see www.sciex.com/trademarks]. Echo®, Echo® MS and Echo® MS+ are trademarks or registered trademarks of Labcyte, Inc. in the United States and other countries, and are being used under license. © 2023 DH Tech. Dev. Pte. Ltd.

